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 2 
Abstract 20 
Infected chronic wounds heal slowly, exhibiting prolonged inflammation, biofilm formation, 21 
bacterial resistance, high exudate and ineffectiveness of systemic antimicrobials. Composite 22 
dressings (films and wafers) comprising polyox/carrageenan (POL-CAR) and 23 
polyox/sodium alginate (POL-SA), loaded with diclofenac (DLF) and streptomycin (STP) 24 
were formulated and tested for antibacterial activity against 2 x 105 CFU/mL of Escherichia 25 
coli, Pseudomonas aeruginosa and Staphylococcus aureus representing infected chronic 26 
wounds and compared with marketed silver dressings. Minimum inhibitory concentration 27 
(MIC) showed higher values for DLF than STP due to non-conventional antibacterial 28 
activity of DLF. The DLF and STP loaded dressings were highly effective against E. coli, 29 
P. aeruginosa and S. aureus. POL-SA dressings were more effective against the three types 30 
of bacteria compared to POL-CAR formulations, whilst the DLF and STP loaded dressings 31 
showed greater antibacterial activity than the silver-based dressings. The films, showed 32 
greater antibacterial efficacy than both wafers and silver dressings. STP and DLF can act 33 
synergistically not only to kill the bacteria but also prevent their resistance and biofilm 34 
formation compared to silver dressings, whilst reducing chronic inflammation associated 35 
with infection.  36 
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1 Introduction 41 
A wound is an interruption in the defensive role of the skin in protecting against 42 
harmful environmental agents [1]. Injury evokes wound healing comprising distinct phases 43 
(haemostasis, inflammation, proliferation, migration and maturation) involving biochemical, 44 
and molecular events that work sequentially towards tissue regeneration [2]. However, 45 
wounds can get contaminated by microorganisms, especially during the proliferation stage 46 
leading to infection. Persistent infection impairs wound healing causing repeating 47 
inflammatory cycle, resulting in chronic wounds [3,4]. Prevention and control of infection 48 
have been identified as essential aspects of wound management [5]. Effective management 49 
requires reducing exogenous microbial contamination, debridement, using appropriate 50 
dressing(s) and administration of topical and systemic broad-spectrum antimicrobial agents 51 
[6]. Topical agents such as povidone iodine and chlorhexidine acid are commonly employed, 52 
though their use is currently restricted to wound cleansing and skin swabs before surgical 53 
incisions [1]. However, antibiotics have high specificity against infection and ultimately 54 
improve wound healing at low concentrations [1,7]. Various commercial dressings have 55 
been developed that release silver to prevent wound infections both in vitro [8] and in vivo 56 
[9]. The emergence of microbial resistance has resulted in the need for more effective 57 
treatments for wound infections [1]. Further, systemic antibiotic treatment is difficult in 58 
chronic wounds such as diabetic foot ulcers due to poor blood circulation at the extremities 59 
of diabetics [6].  60 
Chronic wound infection also causes pain, excessive exudation and patient 61 
discomfort and is a major source of cross-infection particularly antibiotic-resistant species. 62 
Burns for example provide a protein-rich environment, favourable for microbial colonization 63 
[10]. Most infected wounds involve Staphylococcus aureus, Pseudomonas aeruginosa, 64 
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Streptococci and Escherichia coli. S. aureus is considered a challenging microorganism in 65 
wound infections [6] due to its ability to develop resistance against first line antibiotics.  66 
Streptomycin (STP) has been used to treat wound infections [11] and for reducing 67 
infection before skin grafting [12]. It’s reported that diclofenac (DLF) has antibacterial 68 
activity and acts synergistically with STP against Mycobacterium tuberculosis after systemic 69 
administration [13]. Systemic STP in combination with DLF demonstrated synergistic 70 
activity against 45 different strains of mycobacteria [14,15].  71 
This paper reports on the evaluation of antibacterial activity of STP and DLF loaded film 72 
and wafer dressings against S. aureus, E. coli and P. aeruginosa. Minimum inhibitory 73 
concentration (MIC) of STP and DLF in the dressings and in vitro antibacterial efficacy 74 
(zone of inhibition) against the three microorganisms were evaluated using disk diffusion 75 
assay and compared with three commercial silver containing dressings. To the best of our 76 
knowledge, this is the first study comparing the antibacterial performance of streptomycin-77 
diclofenac loaded medicated POL-CAR and POL-SA dressings with commercial silver 78 
loaded antimicrobial dressings for their antibacterial performance.  79 
 80 
2 Methods  81 
 82 
2.1 Materials 83 
(Polyox™ WSR 301 ≈4000 kDa) was a gift from Colorcon Ltd (Dartford, UK), κ-84 
carrageenan (Gelcarin GP 812) was from IMCD Ltd (Sutton, UK), Aquacel® Ag 85 
(ConvaTech, Ltd.), Melgisorb® Ag (Mölnlycke Health Care, Ltd.) were gifted by the 86 
manufacturers and Allevyn® Ag (Smith and Nephew, Ltd) obtained from a local pharmacy. 87 
Nutrient agar and nutrient broth were purchased from Oxoid, UK. Diclofenac sodium, 88 
streptomycin sulphate, glycerol, phosphate buffered saline (PBS) tablets, were purchased 89 
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from Sigma-Aldrich, (Gillingham, UK). Sodium alginate was purchased from Fisher 90 
Scientific (Loughborough, UK). National Collection of Type Culture (NCTC) strains of S. 91 
aureus (A 29213), E. coli (DTCC 25922) and P. aeruginosa (A 10145), were used for 92 
microbiological assays.  93 
 94 
2.2 Preparation of composite polymer based dressings 95 
Composite films and wafers (Table 1) were prepared as previously reported [16,17]. 96 
Polymeric gels of POL-CAR and POL-SA gels were prepared as previously reported 97 
[16,17]. In brief, blends of POL with CAR and POL with SA (weight ratio of 75/25 and 98 
50/50 respectively) yielding 1% w/w of total polymer weight were prepared by stirring on a 99 
magnetic stirrer at 70°C to form a uniform gel (POL-CAR-BLK and POL-SA-BLK). The 100 
composition of the polymers, drugs used for the preparation of gels are summarised in Tables 101 
2 and 3. DL gels of POL-SA and POL-CAR were prepared with 4 ml ethanolic solution of 102 
DLF containing 100 mg and 250 mg of the drug to achieve 10% w/w for POL-SA gel and 103 
for POL-CAR to achieve 25% w/w of DLF in the polymeric gel respectively. These gels 104 
were subsequently cooled to 40°C with constant stirring. Similarly, a 4 ml aqueous solution 105 
containing 250 mg and 300 mg of STP was subsequently added to achieve a final STP 106 
concentration of 25% w/w (POL-SA) and 30% w/w (POL-CAR) in the DL gels.  107 
To obtain films the solutions (25g) were poured into Petri dishes (diameter 90 mm) 108 
and dried in an oven at 40°C for 18h, to obtain the films, while unplasticised polymeric 109 
solutions (10g) were freeze-dried to obtain wafers. To obtain the wafers, 10 gm of each 110 
homogeneous gel was transferred into 6 well moulds (diameter 35 mm) (Thermo-Fisher 111 
Scientific Nunc, Leicestershire UK), placed in a Virtis Advantage XL 70 freeze dryer 112 
(Biopharma Process Systems, Winchester, UK) and lyophilised using the automated 113 
lyophilisation cycle. This involved initially cooling samples from room temperature to -5°C 114 
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and then -50°C over a period of 10 h (at 200 mTorr). An annealing step at -25°C for 2 h was 115 
applied based on the preliminary DSC studies and its effect on the different formulations 116 
was investigated. The frozen samples were then heated in a series of thermal steps to -25°C 117 
under vacuum (20-50 mTorr) over a 24 h period. Secondary drying of the wafers was carried 118 
out at 20°C (10 mTorr) for 7 h.  119 
 120 
2.3 Bacterial sample preparation 121 
Fresh broth cultures were prepared as reported by Labovitiadi et al., [18] by 122 
transferring a single bead unit into 10mL of nutrient broth and incubating for 24h. A loop 123 
full of bacterial culture was streaked onto nutrient agar plate and incubated at 37°C for 24h 124 
to yield separate colonies. Overnight bacterial cultures were centrifuged at 4000 rpm for 10 125 
min in an Accuspin 1 centrifuge (Fisher Scientific, UK), supernatant discarded and pellets 126 
suspended in 20mL of simulated wound fluid (SWF) [16]. This process was repeated twice 127 
and final pellets re-suspended in 5mL SWF, followed by two fold dilutions in SWF. 128 
Bacterial density was determined by measuring the dilute suspension at 500nm to yield the 129 
required density of 2 x 105CFU/mL [18].  130 
 131 
2.4 Minimum inhibitory concentration (MIC) of STP and DLF  132 
The MIC for STP and DLF was evaluated as previously reported [19]. Briefly, three 133 
different stock solutions for each drug were prepared (Table 4) and STP required to obtain 134 
10,000mg/L was calculated using equation 1. Antimicrobial susceptibilities of S. aureus, E. 135 
coli and P. aeruginosa were determined by establishing the MIC using a standard agar 136 
dilution method and 0.25-512mg/L calibration solutions of DLF and STP dilutions also 137 
prepared. 200µL of stock and diluted solutions (10,000mg/L, 1,000mg/L and 100mg/L 138 
respectively) were transferred into a Petri plate and 20mL of nutrient agar (stabilized at 139 
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45°C) added and mixed. The agar was allowed to set at room temperature and 0.1mL of 140 
1×105 CFU/mL of S. aureus, E. coli and P. aeruginosa were spread on separate Petri plates. 141 
These plates were incubated at 37°C for 24h and ensuring that all microorganisms had grown 142 
on drug free control plate. MIC is the lowest concentration of antimicrobial at which there 143 
was no visible growth of organisms. Growth of one or two colonies or a fine film of growth 144 
was disregarded. 145 
𝑊 =
1000
𝑃
× 𝑉 × 𝐶Eq.1 146 
W is the weight of actives (mg) dissolved in volume V (mL), C is final concentration 147 
of solution (multiples of 1,000mg/L), P (785μg/mg) is the potency provided by the 148 
manufacturer. 149 
 150 
2.5 In vitro antibacterial activity of antimicrobial films, wafers and marketed silver 151 
dressings  152 
The disk diffusion method was used for the assessment of the antibacterial activity 153 
of the DL films, wafers and commercial silver dressings. Solutions (2×105 CFU/mL) of each 154 
bacterial strain (S. aureus, E. coli and P. aeruginosa) was prepared as specified above 155 
(section 2.3) and 0.1mL of each strain spread separately on set nutrient agar media. The 156 
inoculated microorganisms were incubated at 37±1°C for 4h to initiate growth of 157 
microorganisms on the inoculated culture medium before placing the films, wafers and 158 
marketed dressings. The films and marketed silver dressings were cut into 2cm diameter disc 159 
shapes. However, due to difficulty of cutting thicker wafers into smaller discs, DL gels (2g) 160 
were free-dried in 2cm diameter containers to obtain the same diameter as the cut film discs. 161 
Further, circular Whatmann® paper discs (2cm diameter), each wetted with reference 162 
solutions (80μL) of STP and DLF at concentrations of 6mg/mL and 5mg/mL respectively 163 
were used as positive controls. Negative controls were BLK films and wafers (2cm diameter) 164 
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without any STP or DLF. The plates were then incubated at 37±1°C for 24 h after which the 165 
end zones of inhibition (ZOI) in millimetres, formed on the medium (n = 3), were measured.  166 
 167 
2.6 Statistical analysis 168 
Statistical data evaluation was performed using two tailed student t-test at 95% 169 
confidence interval (Graph Pad Prism 4 software) with p value < 0.05 as the minimal level 170 
of significance.  171 
 172 
3 Results 173 
3.1 MIC of STP and DLF 174 
The MIC of STP and DLF was determined for known densities (2 x 105 CFU/mL) of 175 
S. aureus P. aeruginosa E. coli commonly associated with infected chronic wounds. The 176 
MICs of STP for S. aureus and E. coli ranged from 4 - 8mg/L but ranged from 8 - 16mg/L 177 
for P. aeruginosa. MIC for DLF against P. aeruginosa was greater than 512mg/L and 256 - 178 
512mg/L for E. coli and S. aureus respectively.  179 
 180 
3.2 Antimicrobial activity of pure STP and DLF controls 181 
The ZOI of the STP and DLF positive controls for S. aureus, P. aeruginosa and E. 182 
coli are shown in Figure 1 (N and O). STP showed significantly (p<0.05) lower ZOI 183 
(3.2±0.1mm) for S. aureus compared to P. aeruginosa and E. coli. The maximum ZOI of P. 184 
aeruginosa was 4.1±0.1mm which was lower compared to E. coli (4.6±0.1mm) and was 185 
statistically significant (p<0.05). DLF did not show ZOI for S. aureus, P. aeruginosa and E. 186 
coli though there was no bacteria growing directly under the DLF disc (Figure 1, E. coli 187 
plate O) implying that their effectiveness alone as antibacterial may be limited application 188 
to infected wounds. 189 
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  190 
3.3 Antibacterial activity of POL-CAR films (2 x 105 CFU/mL) 191 
Figures 2 (A) and 3(A, B and C) show ZOI of POL-CAR-DL and POL-CAR-DL-192 
20% GLY films against S. aureus, P. aeruginosa and E. coli. There was a significant 193 
difference observed for all POL-CAR-DL films against strains of bacteria (compared to 194 
wafers and marketed dressing and DLF, STP discs. POL-CAR-DL and POL-CAR-DL-20% 195 
GLY films showed a smaller ZOI for S. aureus but increased for P. aeruginosa and E. coli. 196 
For S. aureus the ZOI for POL-CAR-DL and POL-CAR-DL-20%GLY films was 197 
3.6±0.1mm and 3.5±0.1mm respectively which was significantly (p<0.05) higher than pure 198 
STP (3.2±0.1mm). For P. aeruginosa, the observed ZOI was higher than S. aureus but less 199 
than E. coli. POL-CAR-DL and POL-CAR-DL-20%GLY films showed similar ZOI 200 
(4.3±0.1mm) for P. aeruginosa which was higher than the control STP (4.1±0.1mm), 201 
however, the difference was not statistically significant (p> 0.05). The maximum ZOI of 202 
POL-CAR-DL and POL-CAR-DL-20%GLY films was 4.8±0.2mm and 4.7±0.1mm 203 
respectively, for E. coli which though higher than 4.6±0.2mm for the control STP were not 204 
statistically significant (p>0.05).  205 
 206 
3.4 Antibacterial activity of POL-SA films (2 x 105 CFU/mL) 207 
Figures 2 (B) and 4 (D, E and F) show the ZOI of POL-SA-BLK, POL-SA-DL and 208 
POL-SA-DL-9% GLY) films for S. aureus, P. aeruginosa and E. coli. For S. aureus, the 209 
observed ZOI for POL-SA-DL and POL-SA-DL-9%GLY films was 4.6±0.2mm and 210 
4.1±0.2mm respectively which was significantly (p<0.05) higher compared to the STP 211 
(3.2±0.1mm) control. The ZOI increased from 4.6±0.2mm (S. aureus) to 4.8±0.2mm (P. 212 
aeruginosa) and 5.0±0.2mm (E. coli) for POL-SA-DL films while for POL-SA-9%GLY 213 
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films it increased from 4.1±0.2mm (S. aureus) to 5.1±0.2mm (P. aeruginosa) and 214 
5.5±0.2mm (E. coli) respectively. 215 
  216 
3.5 Antibacterial activity of POL-CAR and POL-SA wafers (2 x 105 CFU/mL) 217 
Figures 2 (C) and 5 (G, H, I and J) show the ZOI of POL-CAR and POL-SA (BLK 218 
and DL) wafers for S. aureus, P. aeruginosa and E. coli bacterial strains. As was observed 219 
for the films, the BLK (no drug) wafers did not show any ZOIs against all three 220 
microorganisms (Figure 5, G and I). The ZOI of POL-CAR for S. aureus was 3.1±0.1mm 221 
which increased to 3.3±0.1mm for POL-SA whereas STP had a value of 3.2±0.1mm which 222 
was not statistically significant (p>0.05). For P. aeruginosa, the ZOI was higher than S. 223 
aureus but less than E. coli. POL-SA-DL and STP showed similar ZOI of 4.1±0.2mm which 224 
subsequently decreased for POL-CAR-DL (3.9±0.1mm). The maximum ZOI of POL-CAR-225 
DL and POL-SA-DL wafers was respectively 4.5±0.1mm and 4.6±0.3mm for E. coli.  226 
 227 
3.6 Antimicrobial efficacy of marketed wound dressings (2 x 105 CFU/mL) 228 
Figures 2 (D) and 6 (K, L and M) show the ZOI of silver loaded marketed dressings 229 
(Table 5) (Aquacel® Ag, Melgisorb® Ag and Allevyn® Ag) for S. aureus, P. aeruginosa and 230 
E. coli. There were very small ZOIs observed for all three different strains of microorganisms 231 
in the presence of these marketed silver based dressings, though these bacteria were 232 
completely absent in the area directly underneath the dressing as shown in figure 6 inset (M, 233 
S. aureus). The ZOI for S. aureus was increased for Allevyn® Ag foam dressing (2.3 ± 234 
0.1mm) while all three marketed dressings showed a ZOI of 2.0±0.1mm for P. aeruginosa. 235 
The ZOI for E. coli was higher for Allevyn® Ag foam dressing (2.9±0.0mm) compared to 236 
Aquacel® Ag and Melgisorb® Ag (2.0±0.0mm). 237 
4. Discussion 238 
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One of the overall objectives of the broad study was to compare the properties of dense 239 
dressings such as films to corresponding porous formulations such as freeze-dried wafers 240 
relative to commercial silver based dressings. Drying in an oven only yields non porous 241 
films and therefore it was important to freeze-dry other gels in a freeze-dryer. The reason 242 
for plasticising the films, was purely to improve the flexibility and ease of handling, to 243 
fulfil one of the key functional performance requirements for film dressings. The 244 
hypothesis for the comparison, was that the differences in physical properties (porosity), 245 
which are known to significantly affect rate of hydration and swelling, will also 246 
significantly affect the rate of drug diffusion out of the swollen gels and subsequently 247 
affect the degree of antibacterial efficacy. The hypothesis for the comparison, was that the 248 
differences in physical properties (porosity), which are known to significantly affect rate of 249 
hydration and swelling, will also significantly affect the rate of drug diffusion out of the 250 
swollen gels and subsequently affect the degree of antibacterial efficacy.  251 
 Ineffective control of wound infections caused by antibiotic resistant strains of 252 
pathogens has intensified the need to consider modifying current approaches including use 253 
of medicated dressings which can overcome resistance and reduce bacterial biofilm 254 
formation. This study assessed the in vitro antibacterial activity of composite films and 255 
wafers combining antibacterial (STP) and anti-inflammatory (DLF) drugs for targeting two 256 
phases of wound healing. The two drugs were also selected based on their reported 257 
synergistic antibacterial effect when administered systemically [14]. Many texts refer to 258 
bacterial bio-burden greater than 105 CFU/mL organisms per gram of tissue as a criterion 259 
for infection [3,6]. In this study we used 2×105CFU/mL of S. aureus, P. aeruginosa and E. 260 
coli to evaluate antimicrobial efficacy of DL film and wafer dressings and compared their 261 
performance against marketed silver dressings. 262 
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POL-CAR-BLK films did not show any zone against all three different 263 
microorganisms (Figure 3 A) implying that the observed antibacterial effect was solely due 264 
to the presence of STP and DLF. The formulated films, wafers and marketed dressings 265 
showed antibacterial efficacy against bacterial bio-burden 2 x 105 CFU/mL of S. aureus, P. 266 
aeruginosa and E. coli. Both P. aeruginosa and E. coli are Gram-negative microorganisms 267 
and required a higher MIC of STP compared to S. aureus. This means STP is more effective 268 
against the Gram-positive microorganism S. aureus than the Gram-negative E. coli and P. 269 
aeruginosa which is interesting, given the fact the S. aureus and related species are a major 270 
cause of antibiotic resistance [14]. 271 
During the antibacterial study, the films and wafers swelled when placed on the 272 
highly water saturated agar gel under incubation, simulating a broken skin (wound) surface 273 
and this is to be expected. The swelling of the drug loaded polymeric dressings is an 274 
important characteristic as that is important to ensure ease of drug dissolution, diffusion out 275 
of the swollen gel and eventually release to reach the target bacterial organisms. 276 
To kill the bacteria, STP and DLF must interact with the binding site, occupy a 277 
critical number of sites of the bacteria and remain there long enough to inhibit normal 278 
biochemical reactions [20]. It’s been reported that antimicrobial activity is either 279 
concentration or time dependent [21,22]. Concentration dependent drugs include 280 
aminoglycosides (e.g. STP), whose ability to kill bacteria is dependent on the presence of 281 
high concentrations at the site of infection. At least a ratio of 10:1 is required for such 282 
concentration dependent antibiotics to effectively kill bacteria and prevent development of 283 
resistance [21,23,24,25]. On the other hand, drug concentrations above the MIC should 284 
remain for long periods of time at the site of infection in order to achieve antibacterial 285 
action [21,22].  286 
 13 
In previous studies [13,14,15], it has been demonstrated that the concentrations 287 
required to kill S. aureus is higher than P. aeruginosa which is time dependent. DLF required 288 
higher concentrations to kill the bacteria that are beyond those clinically achievable with 289 
antibiotics, implying that DLF on its own could not effectively inhibit P. aeruginosa based 290 
infections. Dutta et al., [14] previously demonstrated that when DLF is used in vitro, it 291 
showed higher MIC values compared to conventional antibiotic drugs such as STP but in 292 
vivo, the amount of DLF required to protect an animal from Mycobacterium spp was much 293 
lower. This suggests that DLF might be used as adjuvant to current to manage bacterial 294 
infections [13,14,15] as was done in this study.  295 
For S. aureus, different ZOIs were observed attributed to the rate of diffusion of STP 296 
and DLF (films and wafers) and silver (commercial) from the dressings. Both POL-CAR; 297 
POL-SA films had significantly higher ZOI suggesting a synergistic action between both 298 
drugs compared to each individual drug (refer to figure1). ZOI was ellipsoidal for POL-SA 299 
films due to the rapid initial swelling and disintegration of the polymer matrix and rapid 300 
diffusion of STP and DLF through the free flowing swollen gels (figure 4 E&F). Bajpai & 301 
Sharma [26] explained that the more rapid swelling of SA is due to the mannuronate block 302 
where Ca2+ binds to the poly gluconate units which starts to disintegrate the swollen matrix 303 
[26]. Differences in the ZOI of POL-CAR-DL and POL-SA-DL formulation could be related 304 
to the two different polymers (CAR and SA), their percentage ratios used and their different 305 
swelling mechanisms (surface wetting, hydration, hydrogel formation and erosion) [17] 306 
which subsequently affects rate of drug diffusion through the matrix and onto the bacterial 307 
colonies. 308 
Maximum ZOI was observed for POL-SA-DL and POL-SA-DL-9%GLY films due 309 
to rapid swelling and subsequently rapid diffusion of both STP and DLF from the swollen 310 
matrix. This supports the swelling and drug release data from previous studies [16,17].  311 
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All the DL films showed greater antibacterial activity compared to wafers which was 312 
interesting. Wafers generally have a higher loading capacity, faster hydration and cumulative 313 
percent drug release compared to films due to their generally more porous nature [27]. 314 
However, it was observed that higher drug loading in the wafers resulted in the formation of 315 
greater amounts of sodium sulphate which decreased the hydration capacity [16,17] of DL 316 
wafers subsequently affecting drug diffusion with a consequent decrease in ZOI compared 317 
to films but greater than the marketed dressings.  318 
From a pharmaceutical perspective, these differences could be associated with the 319 
total amounts of polymer present in films and wafers which resulted in the different 320 
hydration rates and eventually different ZOIs. For example, the weights ranged from 22.1 321 
mg and 30.3 mg for POL-CAR DL films and wafers respectively. This was also true for the 322 
POL-SA DL films and wafers (17.9 mg and 24.6 mg for films and wafers respectively). It 323 
should be noted that though both formulations had similar diameters, their contents were 324 
different as the films were cut out directly from a bigger sheet due to difficulty of removing 325 
a film with small diameter whilst the wafers were cast directly into 2 cm diameter moulds 326 
due to ease of removal. It is very difficult to effectively cut a relatively thick wafer into 327 
circular discs without damaging the structure due to their soft and porous nature.  328 
More interestingly, the formulated film and wafer dressings, showed greater 329 
antibacterial efficacy than marketed silver based antibacterial dressing which showed either 330 
lower or absence of ZOIs for all three different microorganisms even though the area directly 331 
under the discs showed no microbial growth. This may be due to two reasons: (i) the lower 332 
amounts of silver present in these dressings (Figure 6) relative to the combined 333 
concentrations of STP and DLF present in the composite films and wafers and (ii) most 334 
likely due to STP and DLF present in both films and wafers acting synergistically to kill the 335 
bacteria and potentially inhibiting biofilm formation and resistance of the bacteria. DLF 336 
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consists of a secondary amino group and a phenyl ring, both ortho positions of which are 337 
occupied by chlorine atoms. This causes an angle of torsion between the two aromatic rings, 338 
which presents structural similarities with phenothiazine and this is responsible for its 339 
antibacterial activity against microorganisms such as E. coli, S. aureus and P. aeruginosa 340 
[14,15]. DLF’s antibacterial activity involves the inhibition of bacterial DNA synthesis 341 
whereas STP acts by binding to 30S ribosomal subunits in the microorganisms and 342 
disrupting the initiation and elongation steps in protein synthesis. On the other hand, silver 343 
in the presence of moisture, such as wound exudate, readily ionises to release silver ions 344 
(Ag+) which is involved in oxidation reactions by catalysing reactions between oxygen 345 
present in the cell and hydrogen from thiol groups. This results in disulphide bond formation, 346 
ultimately inhibiting cell function due to changes in protein structure, resulting in protein 347 
denaturation and enzyme inhibition [28]. The increased antibacterial activity of the film and 348 
wafer dressings suggests a potential application in chronic wound management. 349 
 Formulations administered for systemic use usually have to overcome the challenges 350 
to drug absorption, metabolism, distribution and elimination before the drug reaches the 351 
target sites for activity, hence such systemic formulations tend not to always have direct in 352 
vitro-in vivo correlations. For formulations such as wound dressings, intended for direct 353 
application, where the drug(s) are in direct contact with the target tissues, a high positive in 354 
vitro – in vivo correlation tends to exist due to minimal pharmacokinetic barriers. 355 
Silver is a widely used anti-microbial agent effective against infection causative 356 
wound pathogens which are responsible for delayed wound healing and can be added to a 357 
range of composite dressings [29]. Silver containing wound dressings release silver ions 358 
which vary due to the different forms (silver sulfadiazine, ionic silver nanoparticles 359 
containing scaffolds, nanofiber containing silver nanoparticles, silver-containing activated 360 
carbon and fibres) and the amount of the silver present [1,30]. Although there are important 361 
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questions raised by Modak et al [31] in regards to the use of silver in infected wounds and 362 
formation of biofilms by the microorganisms, the versatile effect of silver carries a low risk 363 
of resistance even though some studies in burn wounds have shown bacterial resistance to 364 
silver sulfadiazine and silver nitrate by Pseudomonas spp [31]. Moreover, the antimicrobial 365 
effect of silver incorporated in a number of dressings depends on the release rate of silver 366 
ions which influences the overall antimicrobial effect [32]. In comparative antimicrobial 367 
efficacy studies, it was reported that certain types of methicillin resistant strains among S. 368 
aureus, P. aeruginosa, and E. coli were less sensitive to Urgotul SSD®, Bactigras®, 369 
Acticoat®, Askina Calgitrol Ag® and Aquacel Ag® antimicrobial dressings [33]. 370 
Furthermore, in vivo silver can bind to proteins present in biofilms instead of binding to the 371 
bacterial cell walls, resulting in reduced antimicrobial effect against the bacteria [34]. 372 
Another potential concern is that silver does not act speciﬁcally against bacteria but also acts 373 
on any host proteins. Therefore, if very few bacteria counts are present at the wound site, 374 
then the effect on host tissue is greater which could slow down healing [35]. Concentrations 375 
above 1mg/L (1 part per million) of silver reacts with wound exudate and could cause 376 
transient skin staining [36]. Li and co-authors suggested that bacterial resistance could be 377 
induced when low concentrations of silver were used [37]. There is therefore the possibility 378 
of these silver containing dressings inducing resistance from S. aureus and P. aeruginosa 379 
which are known to be able to form biofilms in an infected chronic wound environment [38]. 380 
However, because there was absence of bacteria in the immediate application area beneath 381 
the marketed dressings, it implies the silvers dressing were effective to kill the bacteria in 382 
only the applied area of a wound and could also potentially limit or completely prevent 383 
infection from external sources.  384 
 385 
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5 Conclusion 386 
Composite polymer based dressings containing STP and DLF appear to show 387 
significantly higher inhibition of the three bacterial strains compared to silver containing 388 
commercial dressings. STP can help to reduce bacterial infection by its known antimicrobial 389 
action and potentially in synergy with DLF while the latter can also help to reduce the 390 
swelling and pain associated with injury due to its anti-inflammatory action. However, these 391 
will, require further investigations in an in vitro cell culture (for cell viability and cell 392 
migration/proliferation) and in vivo animal study.  393 
 394 
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FIGURE LEGENDS 521 
Figure 1: ZOI of control STP (N) and control DLF (O) for S. aureus, P. aeruginosa and E. 522 
coli. The inset of control DLF shows the absence of bacteria around the applied area of the 523 
disk (mean ± SD, n = 3). 524 
Figure 2: Extracted data comparing the measured ZOI data (mm) of S. aureus, P. 525 
aeruginosa and E. coli for the various formulations and marketed dressings tested.(A) 526 
POL-CAR (DL and DL-20%GLY) films and STP and DLF (mean ± SD, n = 3). (B) POL-527 
SA-DL and POL-SA-DL-9%GLY films and control STP and DLF (mean ± SD, n = 3). (C) 528 
POL-CAR-DL-An and POL-SA-DL-An wafers and control STP and DLF (mean ± SD, n = 529 
3). (D) The marketed dressings (Aquacel® Ag, Melgisorb® Ag, Allevyn® Ag (mean ± SD, 530 
n=3). 531 
Figure 3: The digital images of ZOI of (A) POL-CAR-BLK, (B) POL-CAR-DL, (C) POL-532 
CAR-DL-20%GLY films observed for S. aureus, P. aeruginosa and E. coli(mean ± SD, 533 
n=3). 534 
Figure 4: The digital images of ZOI of (D) POL-SA-BLK, (B) POL-SA-DL, (C) POL-SA-535 
DL-9%GLY observed for S. aureus, P. aeruginosa and E. coli(mean ± SD, n = 3). 536 
Figure 5: Digital images of ZOI of (G) POL-CAR-BLK-An, (H) POL-CAR-DL-An, (I) 537 
POL-SA-BLK-An, (J) POL-SA-DL-An, observed for S. aureus, P. aeruginosa and E. coli 538 
(mean ± SD, n = 3). 539 
Figure 6: Digital images of ZOI observed for S. aureus, P. aeruginosa and E. coli by (K) 540 
Aquacel® Ag; (L) Melgisorb® Ag; and (M) Allevyn® Ag. Inset shows the absence of bacteria 541 
in the immediate applied area of the dressing (mean ± SD, n = 3). 542 
  543 
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 547 
Table 1: Formulations used to evaluate antimicrobial efficacy against S. aureus, P. 548 
aeruginosa and E. coli. 549 
 550 
Formulation  CODE  
POL-CAR-BLK  A  
POL-CAR-DL  B  
POL-CAR-DL-20%GLY  C  
POL-SA-BLK  D  
POL-SA-DL  E  
POL-SA-DL-9%GLY  F  
POL-CAR-BLK-An  G  
POL-CAR-DL-An  H  
POL-SA-BLK-An  I  
POL-SA-DL-An  J  
Aquacel® Ag  K  
Melgisorb® Ag  L  
Allevyn® Ag  M  
STP  N  
DLF  O  
 551 
  552 
 25 
 553 
Table 2: Quantities of the polymers, drugs and GLY (varying amounts based on total solid 554 
weight) within composite polymer gels used for formulation of POL-CAR and POL-SA 555 
(BLK and DL) films. 556 
Formulation 
 
POL 
(gm) 
CAR 
(gm) 
SA 
(gm) 
GLY 
(gm) 
DLF 
(gm) 
STP 
(gm) 
Total 
weight 
(gm) 
% GLY 
Content 
POL-CAR-BLK 0.75 0.25 - 0.00 - - 1.00 0.00 
POL-CAR-BLK 0.75 0.25 - 0.10 - - 1.10 9.09 
POL-CAR-BLK 0.75 0.25 - 0.25 - - 1.25 20.00 
POL-CAR-BLK 0.75 0.25 - 0.50 - - 1.50 33.33 
POL-CAR-BLK 0.75 0.25 - 0.75 - - 1.75 42.86 
POL-CAR-BLK 0.75 0.25 - 1.00 - - 2.00 50.00 
POL-CAR-DL 0.75 0.25 - 0.00 0.10 0.30 1.40 0.00 
POL-CAR-DL 0.75 0.25 - 0.10 0.10 0.30 1.50 6.67 
POL-CAR-DL 0.75 0.25 - 0.25 0.10 0.30 1.65 15.15 
POL-CAR-DL 0.75 0.25 - 0.50 0.10 0.30 1.90 26.32 
POL-CAR-DL 0.75 0.25 - 0.75 0.10 0.30 2.15 34.88 
POL-CAR-DL 0.75 0.25 - 1.00 0.10 0.30 2.40 41.67 
POL-SA-BLK 0.50 - 0.50 0.00 - - 1.00 0.00 
POL-SA-BLK 0.50 - 0.50 0.10 - - 1.10 9.09 
POL-SA-BLK 0.50 - 0.50 0.25 - - 1.25 20.00 
POL-SA-BLK 0.50 - 0.50 0.50 - - 1.50 33.33 
POL-SA-DL 0.50 - 0.50 0.00 0.05 0.15 1.20 0.00 
POL-SA-DL 0.50 - 0.50 0.10 0.05 0.15 1.30 7.69 
POL-SA-DL 0.50 - 0.50 0.25 0.05 0.15 1.45 17.24 
POL-SA-DL 0.50 - 0.50 0.50 0.05 0.15 1.70 34.48 
 557 
 558 
 559 
 560 
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 565 
 566 
Table 3: Composition of polymers and drugs (varying quantity) present in composite 567 
polymer gels used to produce composite freeze dried POL-CAR and POL-SA (BLK and 568 
DL) wafers. 569 
Pure material POL-CAR-BLK POL-CAR-DL 
(weight in gm) 
POL-SA-BLK POL-SA-DL 
 
POL 0.75 0.75 0.50 0.50 
CAR 0.25 0.25 - - 
SA - - 0.50 0.50 
STP - 0.30 - 0.25 
DLF - 0.25 - 0.10 
Total weight 1.00 1.55 1.00 1.35 
 570 
 571 
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 575 
 576 
Table 4: Stock solutions of STP and DLF used to evaluate MIC of S. aureus, E. coli and P. 577 
aeruginosa (mean ± SD, n = 3). 578 
579 
 Stock solution 1 Stock solution 2 Stock solution 3 
STP 10000 mg/L (254 mg of 
STP + 20 ml of distilled 
water) 
1000 mg/L (1 ml of stock 
solution 1 + 9 ml of distilled 
water) 
100 mg/L (1 ml of stock 
solution 2 + 9 ml of 
distilled water) 
DLF 10000 mg/L (200 mg of 
DLF + 20 ml of distilled 
water) 
1000 mg/L (1 ml of stock 
solution 1 + 9 ml of distilled 
water) 
100 mg/L (1 ml of stock 
solution 2 + 9 ml of 
distilled water) 
 28 
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 587 
Table 5: Description of the silver containing dressings used for antimicrobial study 588 
(Hamberg et al., 2012) (mean ± SD, n = 3). 589 
 590 
Product Formulation details Silver content (mg/cm2) 
Aquacel® Ag Sodium carboxymethylcellulose with 
ionic silver 
0.08-0.09 
Melgisorb® Ag Alginate dressing with silver sodium 
hydrogen zirconium phosphate 
0.08 
Allevyn® Ag Polyurethane foam dressing with soft gel  
adhesive and silver sulphadiazine 
0.90 
 591 
 592 
 593 
  594 
 29 
 595 
 596 
 597 
 598 
Figure 1 599 
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Figure 3 618 
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P. aeruginosa
E. coli
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Figure 4 622 
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S. aureus
P. aeruginosa
E. coli
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Figure 5 639 
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Figure 6 645 
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S. aureus
P. aeruginosa
E. coli
